C3g clinical trials

Explore recruiting c3g clinical trials.

Recruiting c3g studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

C3g trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC‑MPGN

Netherlands, Austria, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients with C3-Glomerulopathy

Austria, Greece, Spain, Czechia, Latvia, Belgium +5 more

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis

Germany, France, Czechia, Netherlands, Greece, Italy +1 more

Phase III and phase IV (Integrated) EU CTIS Study details

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)

Spain, Italy, Czechia, France, Netherlands, Belgium +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Austria, Netherlands, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)

Lithuania, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

C3g trials by city

C3g in Toronto C3g in Vancouver C3g in Montreal C3g in Calgary C3g in Edmonton C3g in Ottawa C3g in Winnipeg C3g in Quebec City C3g in Hamilton C3g in Kitchener C3g in London C3g in Halifax C3g in New York C3g in Los Angeles C3g in Chicago C3g in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease